Compare AstraZeneca plc (AZN) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? AstraZeneca plc trades at $166.5 (market cap $253.13B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.61. The key difference: AstraZeneca plc pays a 1.92% dividend while Vanguard Sht-Term Inflation-Protected Sec Idx ETF pays none, and AstraZeneca plc is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals.
| AZN | VTIP | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | — |
52-Week High | $209.48 | $50.75 |
52-Week Low | $137.44 | $49.39 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
VTIP trades at $49.61, down slightly by 0.06% with a bearish technical signal from moving averages. The ETF focuses on short-term inflation-protected securities, offering investors protection against persistent inflation currently running at 3.8%. Recent institutional activity shows mixed positioning with several firms increasing holdings while others trimmed positions. The overall technical picture remains cautious despite neutral oscillator readings.
VTIP provides inflation hedging with potential 3.8% returns in the current environment, though the Fed's reluctance to cut rates in 2026 presents headwinds. The ETF's short-term TIPS focus reduces duration risk but remains sensitive to inflation expectations and monetary policy shifts. Key risks include interest rate volatility and inflation trajectory uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
